AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22014144 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 18
Study 22014144 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 19894369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin K oxide gel
Number of subjects: 20
Study 19894369 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 16858218 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (3 times a week for 3 months, 1 hour per session at 85% of pain-free walking time)
Number of subjects: 60
Study 16858218 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 60
Study 16858218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 16858218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 12917836 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume data
Number of subjects: 82
Study 12917836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter data
Number of subjects: 82
Study 10699777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric colonoscope (Olympus PCF‐100)
Number of subjects: 150
Study 10699777 — intervention group
Group type: COMPARATOR
Intervention: Adult colonoscope (Olympus CF‐100L)
Number of subjects: 150
Study 10699777 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (including switching colonoscopes)
Number of subjects: 150
Study 10699777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric colonoscope in women with prior hysterectomy
Number of subjects: 150
Study 9234051 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (1 mg)
Number of subjects: 12
Study 9234051 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 8210308 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal cardioversion (30, 50, 100 J delivered via oesophageal electrode)
Number of subjects: 100
Study 8210308 — intervention group
Group type: COMPARATOR
Intervention: Transchest cardioversion (50, 100, 200, 360 J delivered if required)
Number of subjects: 100
Study 8210308 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal cardioversion
Number of subjects: 100
Study 8210308 — intervention group
Group type: COMPARATOR
Intervention: Transchest cardioversion
Number of subjects: 100
Study 8210308 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal cardioversion (energies ≤ 100 J)
Number of subjects: 100
Study 8210308 — intervention group
Group type: COMPARATOR
Intervention: Transchest cardioversion (energies ≤ 100 J)
Number of subjects: 100
Study 2434976 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% tetracaine with 5% Trendelenburg position for 45 s
Number of subjects: 80
Study 2434976 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of 0.5% bupivacaine
Number of subjects: 80
Study 2434976 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine
Number of subjects: 80
Study 2434976 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% tetracaine
Number of subjects: 80
Study 2434976 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 31752648 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of reference (context of more attractive or less attractive images)
Number of subjects: 0
Study 31430733 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced randomized optimization algorithms for PET reconstruction using non-smooth priors.
Number of subjects: 0
Study 31430733 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of about ten projections and backprojections in the PET reconstruction process.
Number of subjects: 0
Study 28176547 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (IIs)
Number of subjects: 62
Study 28176547 — intervention group
Group type: COMPARATOR
Intervention: Rehearsal (RR) encoding strategy
Number of subjects: 62
Study 26391356 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL improvement pattern (24 patients, 6%)
Number of subjects: 416
Study 26391356 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL stability pattern (171 patients, 41%)
Number of subjects: 416
Study 26391356 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL deterioration pattern (78 patients, 19%)
Number of subjects: 416
Study 26391356 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL deterioration pattern (143 patients, 34%)
Number of subjects: 416
Study 23336628 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥180 sec)
Number of subjects: 382
Study 23336628 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (≤10 sec)
Number of subjects: 382
Study 20359723 — intervention group
Group type: EXPERIMENTAL
Intervention: +LCPUFA group
Number of subjects: 60
Study 20359723 — intervention group
Group type: COMPARATOR
Intervention: -LCPUFA group
Number of subjects: 60
Study 19408058 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-based intervention by primary care physicians (PCPs) including cognitive-behavioral, pharmacological, and patient-centered management over 12 months with seven scheduled visits
Number of subjects: 30
Study 19408058 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-based intervention by primary care physicians (PCPs)
Number of subjects: 30
Study 17869598 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 50
Study 17869598 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine ointment
Number of subjects: 50
Study 15638067 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical comfrey product Traumaplant (10% active ingredient)
Number of subjects: 203
Study 15638067 — intervention group
Group type: COMPARATOR
Intervention: 1% comfrey product (control)
Number of subjects: 203
Study 11846008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bakers yeast)
Number of subjects: 58
Study 11846008 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin (EPO; 3 times a week with 2,000 U after each HD session)
Number of subjects: 58
Study 11846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐rich yeast (300 microg 3 times a week after each HD)
Number of subjects: 58
Study 11846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐rich yeast plus EPO (300 microg Se and 2,000 U EPO 3 times a week after each HD)
Number of subjects: 58
Study 11846008 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 58
Study 9670383 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at four acupoints (Chung Chi CV3, Kuan Yuan CV4, bilateral Tzu Liao UB32) plus conventional intermittent catheterization program (ICP)
Number of subjects: 80
Study 9670383 — intervention group
Group type: COMPARATOR
Intervention: Conventional bladder training program with ICP only
Number of subjects: 80
Study 9670383 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture within 3 weeks after injury
Number of subjects: 80
Study 9670383 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture after 3 weeks after injury
Number of subjects: 80
Study 8149361 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg orally, twice a day)
Number of subjects: 10
Study 8149361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3243175 — intervention group
Group type: EXPERIMENTAL
Intervention: Furadantine MC 100 mg tid
Number of subjects: 16
Study 3243175 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridurine 100 mg tid
Number of subjects: 16
Study 3243175 — intervention group
Group type: EXPERIMENTAL
Intervention: Urfadyn PL 100 mg bid
Number of subjects: 16
Study 3243175 — intervention group
Group type: EXPERIMENTAL
Intervention: Furadantine MC 100 mg qid
Number of subjects: 16
Study 31364889 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 (1 mg/100 mg, 0.5 mg/100 mg, 0.5 mg/50 mg, 0.25 mg/50 mg)
Number of subjects: 1835
Study 31364889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1835
Study 31364889 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 and Placebo
Number of subjects: 1835
Study 28741903 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected nasal swabs
Number of subjects: 100
Study 26295664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy
Number of subjects: 42
Study 23389382 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (10-week treatment)
Number of subjects: 41
Study 23389382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10-week treatment)
Number of subjects: 41
Study 23389382 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison (DD vs HC)
Number of subjects: 41
Study 22340221 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided group (Group A, BIS monitored and maintained between 40 - 60)
Number of subjects: 5228
Study 22340221 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, BIS monitored but screen covered)
Number of subjects: 5228
Study 22340221 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided group
Number of subjects: 5228
Study 22340221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5228
Study 19680131 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 3
Study 19680131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 3
Study 19680131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 3
Study 17296917 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cannabis (3.56% tetrahydrocannabinol)
Number of subjects: 50
Study 17296917 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 50
Study 15298423 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (Group I)
Number of subjects: 23
Study 15298423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (Group II)
Number of subjects: 23
Study 12923404 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/day moxonidine
Number of subjects: 177
Study 12923404 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day nitrendipine
Number of subjects: 177
Study 9988808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg orally every 12 hours for 6 doses)
Number of subjects: 20
Study 9988808 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (5 mg orally every 4 hours for 72 hours)
Number of subjects: 20
Study 8787984 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-free sib-pair linkage analysis using 360 highly polymorphic marker loci
Number of subjects: 0
Study 8787984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sib-pair linkage analysis with deletion of parental marker genotypic information
Number of subjects: 0
Study 8787984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sib-pair linkage analysis with misspecified marker allele frequency estimates
Number of subjects: 0
Study 8787984 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage testing procedure using a 10 or 20 cM map
Number of subjects: 0
Study 2148827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 20
Study 2148827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) (0.5 mg)
Number of subjects: 20
Study 2148827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of salbutamol and ipratropium bromide
Number of subjects: 20
Study 2148827 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nebulizer treatment (salbutamol, ipratropium bromide, mixture)
Number of subjects: 20
Study 2148827 — intervention group
Group type: COMPARATOR
Intervention: Laboratory assessments
Number of subjects: 20
Study 2148827 — intervention group
Group type: COMPARATOR
Intervention: Laboratory response
Number of subjects: 20
Study 2148827 — intervention group
Group type: COMPARATOR
Intervention: Hospital study
Number of subjects: 20
Study 7437277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 1.0 g
Number of subjects: 264
Study 7437277 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1.0 g
Number of subjects: 264
Study 7437277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 7437277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 1.0 g (tooth extraction)
Number of subjects: 264
Study 7437277 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1.0 g (tooth extraction)
Number of subjects: 264
Study 31902311 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (600 mg·day-1 CurraNZ™)
Number of subjects: 14
Study 31902311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg microcrystalline cellulose)
Number of subjects: 14
Study 29788230 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab/Pertuzumab-based chemotherapy
Number of subjects: 225
Study 29788230 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TIL percentage
Number of subjects: 225
Study 29692179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous belimumab plus standard therapy
Number of subjects: 0
Study 29692179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab plus standard therapy
Number of subjects: 0
Study 29692179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27154424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU fortnightly for 6 months)
Number of subjects: 90
Study 27154424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 24916911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 24916911 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 21409548 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic route (RPR)
Number of subjects: 88
Study 21409548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator route (TOR)
Number of subjects: 88
Study 21302741 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing hydroxyapatite
Number of subjects: 150
Study 21302741 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium peroxide
Number of subjects: 150
Study 21302741 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (no active ingredient)
Number of subjects: 150
Study 21302741 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (hydroxyapatite, calcium peroxide, placebo)
Number of subjects: 150
Study 17573642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal tonometer
Number of subjects: 205
Study 17573642 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 205
Study 17573642 — intervention group
Group type: COMPARATOR
Intervention: Pneumotonometry
Number of subjects: 205
Study 16239629 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy
Number of subjects: 2155
Study 16239629 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin therapy
Number of subjects: 2155
Study 12082358 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (gonadotropin-releasing hormone) administered via four monthly injections and estradiol patch during testing
Number of subjects: 16
Study 12082358 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 women tested in the follicular phase of their menstrual cycles)
Number of subjects: 16
Study 10399993 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1,500,000 IU over 30 to 60 min)
Number of subjects: 219
Study 10399993 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI grade 3 flow
Number of subjects: 219
Study 10399993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 219
Study 10399993 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 219
Study 10399993 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial score
Number of subjects: 219
Study 10399993 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic volume index
Number of subjects: 219
Study 7872446 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% clotrimazole
Number of subjects: 54
Study 7872446 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% miconazole
Number of subjects: 54
Study 29447733 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke risk model based on older age, Killip class 3 or 4, estimated glomerular filtration rate ≤45 ml/min/1.73 m2, hypertension history, and previous stroke.
Number of subjects: 22904
Study 29447733 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke risk score sextiles (1.8%, 2.9%, 4.1%, 5.6%, 8.3%, and 10.9% event rates for increasing risk).
Number of subjects: 22904
Study 28851323 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 °C cold water immersion (CS)
Number of subjects: 17
Study 25623485 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (standard arm)
Number of subjects: 454
Study 25623485 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (carbapenem-sparing arm)
Number of subjects: 454
Study 23110916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 126
Study 23110916 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 126
Study 21402752 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalling immoral behavior
Number of subjects: 3
Study 21402752 — intervention group
Group type: COMPARATOR
Intervention: Recalling moral behavior
Number of subjects: 3
Study 18595128 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 weeks of pegylated interferon and ribavirin treatment for genotype 1-infected slow responders
Number of subjects: 0
Study 18595128 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks of pegylated interferon and ribavirin treatment for genotype 1-infected slow responders
Number of subjects: 0
Study 16980814 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1/2 genetic testing
Number of subjects: 157
Study 12562461 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization treatment
Number of subjects: 59
Study 12562461 — intervention group
Group type: COMPARATOR
Intervention: Strict elimination diet (Control)
Number of subjects: 59
Study 10836202 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with 50 micrograms/day of 17 beta‐estradiol
Number of subjects: 22
Study 10836202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9098205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) at a dose of 0.16 mg/kg/min
Number of subjects: 140
Study 9098205 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (DIP) at a dose of 0.56 mg/kg
Number of subjects: 140
Study 9098205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 140
Study 8473679 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY u 3405 (20 mg, single oral dose)
Number of subjects: 0
Study 8473679 — intervention group
Group type: COMPARATOR
Intervention: PG D2 nasal insufflation
Number of subjects: 0
Study 3701114 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0
Study 3701114 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitazato warming kit (Group A - KK)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sage warming kit (Group B - KS)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitazato warming kit (Group C - SK)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sage warming kit (Group D - SS)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: KK (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: KS (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: SK (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: SS (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: SH (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: HK (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: HS (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: HH (patients' own oocytes)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: eKK (egg-donation-derived embryos)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: eKS (egg-donation-derived embryos)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: eSK (egg-donation-derived embryos)
Number of subjects: 169
Study 30074129 — intervention group
Group type: EXPERIMENTAL
Intervention: eSS (egg-donation-derived embryos)
Number of subjects: 169
Study 28541645 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d plus antipsychotics
Number of subjects: 200
Study 28541645 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus antipsychotics
Number of subjects: 200
Study 23557025 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 20 mg b.i.d. for 3 months
Number of subjects: 64
Study 23557025 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment only (Control)
Number of subjects: 64
Study 23712985 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood appetitive traits (Desire to Drink, Enjoyment of Food, Satiety Responsiveness)
Number of subjects: 213
Study 23712985 — intervention group
Group type: COMPARATOR
Intervention: Having two obese parents
Number of subjects: 213
Study 23712985 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Desire to Drink (DD) and decreasing Satiety Responsiveness (SR)
Number of subjects: 213
Study 20946157 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux (3 mg)
Number of subjects: 757
Study 20946157 — intervention group
Group type: COMPARATOR
Intervention: Idraparinux (2.5 mg)
Number of subjects: 757